Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Interest & Investment Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Interest & Investment Income for 11 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 48.33% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 10.93% decrease, with the full-year FY2025 number at $6.6 million, down 10.93% from a year prior.
  • Interest & Investment Income was $1.3 million for Q4 2025 at Cartesian Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.6 million in Q3 2024 to a low of $9000.0 in Q4 2021.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 95.0% in 2021, then soared 12577.78% in 2022.
  • Cartesian Therapeutics' Interest & Investment Income stood at $9000.0 in 2021, then skyrocketed by 12577.78% to $1.1 million in 2022, then fell by 17.62% to $940000.0 in 2023, then skyrocketed by 161.06% to $2.5 million in 2024, then tumbled by 48.33% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Interest & Investment Income are $1.3 million (Q4 2025), $1.5 million (Q3 2025), and $1.7 million (Q2 2025).